The Journal of Experimental Medicine
ELISpot, FluoroSpot and ELISA kits from Mabtech
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published 15 September 2003. doi:10.1084/jem.20022058
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 186K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Amyes, E.
Right arrow Articles by Callan, M. F.C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Amyes, E.
Right arrow Articles by Callan, M. F.C.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
© Rockefeller University Press, 0022-1007/2003/9/903 $5.00
The Journal of Experimental Medicine, Volume 198, Number 6, 903-911

Characterization of the CD4+ T Cell Response to Epstein-Barr Virus during Primary and Persistent Infection

Elisabeth Amyes1, Chris Hatton2, Damien Montamat-Sicotte1, Nancy Gudgeon3, Alan B. Rickinson3, Andrew J. McMichael1 and Margaret F.C. Callan1

1 Medical Research Council (MRC) Human Immunology Unit, Weatherall Institute of Molecular Medicine
2 Department of Haematology, The John Radcliffe, OX3 9DS Oxford, United Kingdom
3 Cancer Research UK Institute for Cancer Studies, University of Birmingham, Edgbaston, B15 2TT Birmingham, United Kingdom

Address correspondence to Margaret Callan, MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, The John Radcliffe, OX3 9DS Oxford, United Kingdom. Phone: 44-1865-222448; Fax: 44-1865-222502; email: mcallan{at}molbiol.ox.ac.uk

The CD8+ T cell response to Epstein-Barr virus (EBV) is well characterized. Much less is known about the evolution of the CD4+ T cell response. Here we show that EBV stimulates a primary burst of effector CD4+ T cells and this is followed by a period of down-regulation. A small population of EBV-specific effector CD4+ T cells survives during the lifelong persistent phase of infection. The EBV-specific effector CD4+ T cells accumulate within a CD27+ CD28+ differentiation compartment during primary infection and remain enriched within this compartment throughout the persistent phase of infection. Analysis of CD4+ T cell responses to individual epitopes from EBV latent and lytic cycle proteins confirms the observation that the majority of the effector cells express both CD27 and CD28, although CD4+ T cells specific for lytic cycle antigens have a greater tendency to express CD45RA than those specific for the latent antigens. In clear contrast, effector CD4+ T cells specific for cytomegalovirus (CMV) accumulate within the CD27- CD28+ and CD27- CD28- compartments. There are striking parallels in terms of the differentiation of CD8+ T cells specific for EBV and CMV. The results challenge current ideas on the definition of memory subsets.

Key Words: immunity • antigens CD27 • antigens CD28 • Epstein-Barr virus • cytomegalovirus


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS